Specific cases of locally advanced or metastatic UC (single or in combination with enfortumab vedotin); unresectable, metastatic or progressed cases of MSI‐H or dMMR solid tumours or locally advanced unresectable or metastatic MSI‐H or dMMR CRC; locally advanced unresectable or metastatic Her2‐positive gastric cancer or GEJ adenocarcinoma (in combination with trastuzumab and chemotherapy); locally advanced, unresectable or metastatic Her2‐negative gastric cancer or GEJ adenocarcinoma (in combination with chemotherapy). Here, ERBB2 is linked to gastric cancer.